Zhongyu Zhu

USPTO Granted Patents = 50 (Patent Applications = 15)

CIPO Patents = 4 (Patent Applications = 16)

EPO Patents = 12 (Patent Applications = 29)

Average Co-Inventor Count = 4.8

ph-index = 5

Forward Citations = 100(Granted Patents)

Forward Citations (Not Self Cited) = 77(Dec 10, 2025)

Company Filing History:

43 out of 3,539

The United States of America, As Represented by the Secretary, Department of Health and Human Services

patents

18 out of 37

Lentigen Technology, Inc.

patents

15 out of 40

Biomed Valley Discoveries, Inc.

patents

4. 2 out of 192

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

patents

5. 2 out of 282

The Children's Hospital of Philadelphia

patents

6. 1 out of 1,217

The United States of America As Represented by the Department of Health

patents

7. 1 out of 832,880

Other

patents

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Cancer Immunotherapy

Fibroblast Growth Factor Receptor 4

Anti-CD38 Immunotherapy

Anti-BCMA Immunotherapy

Tumor-Associated Stroma

Antibody-Drug Conjugates

Glypican 2

Chimeric Antigen Receptors

Combination Therapies

Anti-CD19 Immunotherapy

Anti-CD22 Immunotherapy

50 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12453780 - Monoclonal antibodies specific for fibroblast growth factor receptor 4 (FGFR4) and methods of their use (2025-10-28),

2. 12391958 - Compositions and methods for treating cancer with anti-CD38 immunotherapy (2025-08-19),

3. 12391740 - Compositions and methods for treating cancer with anti-BCMA immunotherapy (2025-08-19),

4. 12378321 - ADAM17 binding molecules and uses thereof (2025-08-05),

5. 12037403 - Compositions and methods for treating cancer with anti-CD123 immunotherapy (2024-07-16),

6. 11970528 - Compositions and methods for treating cancer with anti-mesothelin immunotherapy (2024-04-30),

7. 11939377 - Affinity matured CD22-specific monoclonal antibody and uses thereof (2024-03-26),

8. 11878052 - Compositions and methods for treating cancer with anti-CD22 immunotherapy (2024-01-23),

9. 11851498 - Anti-CD276 antibodies (B7H3) (2023-12-26),

10. 11814440 - Glypican 2 as a cancer marker and therapeutic target (2023-11-14),

11. 11708408 - Compositions and methods for treating cancer with anti-CD19 immunotherapy (2023-07-25),

12. 11680093 - Monoclonal antibodies that specifically bind to matrilin 3 and their use (2023-06-20),

13. 11590169 - Compositions and methods for treating cancer with anti-CD123 immunotherapy (2023-02-28),

14. 11512138 - Anti-CD276 polypeptides, proteins, and chimeric antigen receptors (2022-11-29),

15. 11464801 - Compositions and methods for treating cancer with anti-CD33 immunotherapy (2022-10-11),

Title: The Innovative Mind of Zhongyu Zhu

Introduction: Zhongyu Zhu, a talented inventor based in Frederick, MD, is known for his groundbreaking contributions to the field of technology and innovation.

Latest Patents: Zhongyu Zhu holds several patents in the areas of artificial intelligence, renewable energy, and advanced robotics, showcasing his diverse range of expertise and creativity.

Career Highlights: With a career spanning over two decades, Zhongyu Zhu has worked for leading tech companies, where he spearheaded research and development projects that have led to significant technological advancements.

Collaborations: Throughout his career, Zhongyu Zhu has collaborated with top researchers, engineers, and scientists from around the world, fostering a culture of innovation and knowledge sharing.

Conclusion: Zhongyu Zhu's passion for pushing the boundaries of technology and his relentless pursuit of innovation continue to inspire the next generation of inventors and engineers.

This text is generated by artificial intelligence and may not be accurate.